» Articles » PMID: 21366922

Virus-associated Hemophagocytic Syndrome As a Major Contributor to Death in Patients with 2009 Influenza A (H1N1) Infection

Abstract

Introduction: Virus-associated hemophagocytic syndrome (VAHS) is a severe complication of various viral infections often resulting in multiorgan failure and death. The purpose of this study was to describe baseline characteristics, development of VAHS, related treatments and associated mortality rate of consecutive critically ill patients with confirmed 2009 influenza A (H1N1) infection and respiratory failure.

Methods: We conducted a prospective observational study of 25 critically ill patients with 2009 influenza A (H1N1) infection at a single-center intensive care unit in Germany between 5 October 2009 and 4 January 2010. Demographic data, comorbidities, diagnosis of VAHS, illness progression, treatments and survival data were collected. The primary outcome measure was the development of VAHS and related mortality. Secondary outcome variables included duration of mechanical ventilation, support of extracorporeal membrane oxygenation and duration of viral shedding.

Results: VAHS developed in 9 (36%) of 25 critically ill patients with confirmed 2009 influenza A (H1N1) infection, and 8 (89%) of them died. In contrast, the mortality rate in the remaining 16 patients without VAHS was 25% (P = 0.004 for the survival difference in patients with or without VAHS by log-rank analysis). The patients were relatively young (median age, 45 years; interquartile range (IQR), 35 to 56 years of age); however, 18 patients (72%) presented with one or more risk factors for a severe course of illness. All 25 patients received mechanical ventilation for severe acute respiratory distress syndrome and refractory hypoxemia, with a median duration of mechanical ventilation of 19 days (IQR, 13 to 26 days). An additional 17 patients (68%) required extracorporeal membrane oxygenation for a median of 10 days (IQR, 6 to 19 days).

Conclusions: The findings of this study raise the possibility that VAHS may be a frequent complication of severe 2009 influenza A (H1N1) infection and represents an important contributor to multiorgan failure and death.

Citing Articles

Etoposide Therapy of Cytokine Storm Syndromes.

Henter J, von Bahr Greenwood T Adv Exp Med Biol. 2024; 1448:525-551.

PMID: 39117837 DOI: 10.1007/978-3-031-59815-9_35.


The comparison of the mortality rates of plasmapheresis/hemoperfusion therapy with current treatment among Covid-19 patients.

Kelachayeh S, Shoushtari M, Mehraban Z, Dargahi-Malamir M, Alizadehattar G, Raji H Heliyon. 2022; 8(11):e11282.

PMID: 36310635 PMC: 9597561. DOI: 10.1016/j.heliyon.2022.e11282.


A purine metabolic checkpoint that prevents autoimmunity and autoinflammation.

Saveljeva S, Sewell G, Ramshorn K, Cader M, West J, Clare S Cell Metab. 2022; 34(1):106-124.e10.

PMID: 34986329 PMC: 8730334. DOI: 10.1016/j.cmet.2021.12.009.


COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

Hasselbalch H, Skov V, Kjaer L, Ellervik C, Poulsen A, Poulsen T Cytokine Growth Factor Rev. 2021; 60:28-45.

PMID: 33992887 PMC: 8045432. DOI: 10.1016/j.cytogfr.2021.03.006.


Increased Serum Levels of sCD14 and sCD163 Indicate a Preponderant Role for Monocytes in COVID-19 Immunopathology.

Gomez-Rial J, Curras-Tuala M, Rivero-Calle I, Gomez-Carballa A, Cebey-Lopez M, Rodriguez-Tenreiro C Front Immunol. 2020; 11:560381.

PMID: 33072099 PMC: 7538662. DOI: 10.3389/fimmu.2020.560381.


References
1.
Harms P, Schmidt L, Smith L, Newton D, Pletneva M, Walters L . Autopsy findings in eight patients with fatal H1N1 influenza. Am J Clin Pathol. 2010; 134(1):27-35. DOI: 10.1309/AJCP35KOZSAVNQZW. View

2.
Chowell G, Bertozzi S, Colchero M, Lopez-Gatell H, Alpuche-Aranda C, Hernandez M . Severe respiratory disease concurrent with the circulation of H1N1 influenza. N Engl J Med. 2009; 361(7):674-9. DOI: 10.1056/NEJMoa0904023. View

3.
Imashuku S, Teramura T, Tauchi H, Ishida Y, Otoh Y, Sawada M . Longitudinal follow-up of patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Haematologica. 2004; 89(2):183-8. View

4.
Henter J, Palmkvist-Kaijser K, Holzgraefe B, Bryceson Y, Palmer K . Cytotoxic therapy for severe swine flu A/H1N1. Lancet. 2010; 376(9758):2116. DOI: 10.1016/S0140-6736(10)61345-1. View

5.
Panning M, Eickmann M, Landt O, Monazahian M, Olschlager S, Baumgarte S . Detection of influenza A(H1N1)v virus by real-time RT-PCR. Euro Surveill. 2009; 14(36). View